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NKTR-214 synergizes with radiotherapy to drive tumor regression
Combined anti-PD-1 and anti-LAG-3 checkpoint blockade 
enhances CD8+ TIL effector function and improves overall survival
Methods
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Figure 2. Dual aPD-1/aLAG-3 blockade enhances CD8+ TIL effector 
function. A-D) CT26 tumor-bearing mice were treated as in Fig 1. B) Predicted responders (R) 
were determined by an overall reduction in tumor size (d10-d17), non-responders (NR) had a net 
increase in tumor size. A,C-D) Day 17, tumors were harvested for analysis by flow cytometry.
* ** *
Figure 1. Dual aPD-1/aLAG-3 blockade enhances tumor 
regression and survival. CT26 cells were implanted in BALB/c 
mice (day 0). Tumor-bearing mice were treated with aPD-1 and/or aLAG-3 
mAb (days 7, 10, 13; 10 mg/kg; ip). Tumor growth (area; mm2) was mea-
sured 2x/week and mice were sacrificed when tumors were >150mm2.
Conclusions
Figure 3. Dual aPD-1/aLAG-3 increases myeloid expression of 
PD-L1. CT26 tumor-bearing mice were treated/analyzed as in Fig 2.
Figure 4. CD8 depletion 
abrogates effects of dual 
therapy; CD4 depletion  
dramatically increases 
survival. CT26 tumor-bearing 
mice were treated as in Fig. 1 or 
also given aCD8/aCD4  depleting 
mAbs, d6 vs IgG alone.
Eects of T cell Depletion on Ecacy 
 aPD-1/aLAG-3 therapy enhances tumor regression and survival
Responders to dual therapy display increased CD8+T cell effector 
function: Ki-67, GzmA, TNFa, & IFNg
    
Treg  & Teff populations: Increased proliferation & expression of 
LAG-3 correlate with response
Dual aPD-1/aLAG-3 increases myeloid expression of PD-L1
CD8 depletion abrogates effects of dual therapy; CD4 depletion  
dramatically increases survival
-TESARO, Inc.
-Providence Portland Medical Foundation
-EACRI Cancer Research Animal Division
Checkpoint inhibition is a potent strategy to reinvigorate T cells. 
However, aCTLA-4 or aPD-1 monotherapy has not been effective for the 
majority of patients, resulting in the exploration of combinatorial 
approaches to improve treatment efficacy. One such target is LAG-3, 
which is upregulated on T cells that have experienced repeated antigen 
exposure, such as in the tumor microenvironment (TME), and is 
associated with reduced T cell effector function. In addition, high LAG-3 
expression on regulatory T cells (Tregs) has been reported for patients 
with varying cancer types, providing an additional rationale for targeting 
LAG-3 with the aim of reducing immune suppression within the TME. 
We hypothesized that the combination of aPD-1 and aLAG-3 would 
synergize to promote tumor regression and increase survival via a 
reduction in tumor-induced immune suppression and enhanced CD8+ T 
cell effector function. 
1X106 CT26 cells were implanted in the flank of BALB/c mice. For 
survival expereiments, tumors were measured 2x/week. Mice were 
sacrificed when tumors were >150mm2. For TIL analysis, tumors were 
digested and immune cells analyzed by flow cytometry. Statistics were 
analyzed by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P 
-EACRI Flow Core 
Acknowledgements
Days Post Implant
A B 
D 
C 
0
1800
1800
2000
2200
2400
2600
2800
3000
LA
G
3 
M
FI
CD8
*
**
R
NR
N
.S
.
R
NR
* R
NR
**
*
